Paroxysmal Hypertension Associated With Presyncope.

Presentation of the Patient A 62-year-old woman with a history of well-controlled hypertension was urgently referred to the Vanderbilt Hypertension Clinic for evaluation of worsening hypertension with increasing blood pressure lability. The referral was initiated by her primary physician after measuring her in-office systolic blood pressure to be >300 mm Hg, despite treatment with amlodipine 5 mg, losartan 100 mg, and hydrochlorothiazide 12.5 mg daily. No other new medications had been recently started, and in particular, she was not taking nonsteroidal anti-inflammatory drugs. She meticulously recorded her home blood pressure and documented presyncope with hypotension in the mornings (87/66 mm Hg), which resolved with lying down. In the evening, blood pressure increased in the range systolic of 190 to 200 mm Hg. She also reported symptoms associated with hypertension, including visual difficulty, palpitations, tachycardia, a “hot feeling” in the head, and throbbing headaches. In particular, she described her visual disturbance as a “black curtain coming down over her eyes.” Her husband and other observers described her as “ashen” or “like a ghost,” but on one occasion she was described as being intensely red in the face, appearing flushed. We were fortunate in that her husband was trained as an accountant, so he came to the clinic with her blood pressures recorded in a spreadsheet, which he had frequently documented during the day. Her blood pressure increased during the day, reaching a peak in the early evening, and it was at this point that she had symptomatology such as visual disturbance (Figure 1). However, the following morning, her blood pressure would be low. This pattern repeated again the following day. She had orthostatic hypotension with symptoms on the third morning of observation. During episodes of elevated blood pressure, she had corresponding tachycardia. The heart rate correlated with systolic blood pressure up to levels of ≈160 mm Hg (Figure 1C). Her medical history included mild diabetes mellitus, which was treated by diet alone, hypothyroidism, chronic low back pain associated with muscle spasm, neck pain, and generalized anxiety. She was prescribed additional medications, including simvastatin 20 mg daily, tizanidine 4 mg three times daily, and levothyroxine 0.125 mg daily. She did not smoke tobacco, drink alcohol excessively, or use cocaine. She had no family history of early-onset hypertension or endocrine tumors. On physical exam, her systolic pressure was 186/92 mm Hg, heart rate was 84, and body mass index was 34 kg/m. Fundoscopic exam revealed some copper wiring and arteriovenous nicking, and the physical examination was otherwise normal with no radial-femoral pulse delay. ECG was normal and demonstrated no left ventricular hypertrophy and no repolarization abnormality.

[1]  Wei-Qi Wei,et al.  Co‐Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine‐Associated Hypotension: A Retrospective Cohort Study , 2018, Clinical pharmacology and therapeutics.

[2]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[3]  S. Inomata,et al.  Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics , 2010, Journal of clinical pharmacology.

[4]  J. D. Runyan,et al.  A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients , 2008, International journal of clinical practice.

[5]  P. Neuvonen,et al.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. , 2006, British journal of clinical pharmacology.

[6]  P. Neuvonen,et al.  Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2 , 2005, Clinical pharmacology and therapeutics.

[7]  P. Neuvonen,et al.  Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2–mediated presystemic metabolism , 2004, Clinical pharmacology and therapeutics.

[8]  J. Karemaker,et al.  Baroreflex failure: a neglected type of secondary hypertension. , 2004, The Netherlands journal of medicine.

[9]  P. Neuvonen,et al.  Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction , 2004, Clinical pharmacology and therapeutics.

[10]  D. Goldstein,et al.  Baroreflex Failure as a Late Sequela of Neck Irradiation , 2003, Hypertension.

[11]  I. Biaggioni,et al.  Four Faces of Baroreflex Failure: Hypertensive Crisis, Volatile Hypertension, Orthostatic Tachycardia, and Malignant Vagotonia , 2002, Circulation.

[12]  O. Kuchel Peripheral dopamine in hypertension and associated conditions , 1999, Journal of Human Hypertension.

[13]  U. Fuhr,et al.  Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 , 1999, Clinical pharmacology and therapeutics.

[14]  J. Netterville,et al.  The diagnosis and treatment of baroreflex failure. , 1993, The New England journal of medicine.

[15]  B. Garrett,et al.  Lofexidine in the Treatment of Hypertension: A Twice‐Daily versus Once‐Daily Dose Comparison with 24‐Hour Blood Pressure Monitoring , 1981, Journal of clinical pharmacology.

[16]  P. Hamet,et al.  Free and Conjugated Dopamine in Pheochromocytoma, Primary Aldosteronism and Essential Hypertension , 1979, Hypertension.

[17]  P. Boer,et al.  Clonidine withdrawal. Mechanism and frequency of rebound hypertension. , 1979, British journal of clinical pharmacology.

[18]  C. Dollery,et al.  CLONIDINE WITHDRAWAL IN HYPERTENSION Changes in Blood-pressure and Plasma and Urinary Noradrenaline , 1977, The Lancet.